Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | PTGER1 | P34995 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 2/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5472935 | 0.99 | SLC6A4 (0.53) | SLC6A4HTR6PTGER1MEN1KMT2A | |
| SCHEMBL7667342 | 0.97 | SLC6A4 (0.51) | SLC6A4HTR6PTGER1MEN1KMT2A | |
| SCHEMBL18783932 | 0.93 | MEN1 (0.49) | SLC6A4HTR6PTGER1MEN1KMT2A | |
| SCHEMBL30902367 | 0.93 | MEN1 (0.49) | SLC6A4HTR6PTGER1MEN1KMT2A | |
| SCHEMBL2424456 | 0.86 | MEN1 (0.45) | SLC6A4HTR6PTGER1MEN1KMT2A | |
| SCHEMBL12462495 | 0.84 | PARP10 (0.51) | HPGDSRC | |
| SCHEMBL30679664 | 0.83 | PTGDR2 (0.54) | SLC6A4HTR6PTGER1KMT2AHPGD | |
| SCHEMBL5463136 | 0.81 | PTGDR2 (0.55) | SLC6A4HTR6PTGER1HPGDPTGDR2 | |
| SCHEMBL16150607 | 0.81 | HTR2C (0.46) | SLC6A4HTR6PTGER1MEN1KMT2A | |
| SCHEMBL3851835 | 0.79 | SRC (0.63) | MEN1KMT2AHPGDPTGDR2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | SLC6A4 4389/4885HTR6 1658/4885PTGER1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.